Mirador Capital Partners LP increased its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 28.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,355 shares of the conglomerate's stock after purchasing an additional 6,492 shares during the period. Mirador Capital Partners LP's holdings in Danaher were worth $6,504,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Danaher during the 2nd quarter worth about $10,492,520,000. Jupiter Topco LLC acquired a new position in Danaher during the second quarter worth approximately $1,456,317,000. Generation Investment Management LLP purchased a new position in Danaher during the second quarter worth approximately $1,287,949,000. Bank of America Corp DE acquired a new position in shares of Danaher in the 2nd quarter valued at $993,846,000. Finally, Legal & General Group Plc purchased a new stake in shares of Danaher during the 2nd quarter valued at $801,056,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. Guggenheim lifted their target price on Danaher from $200.00 to $250.00 and gave the company a "buy" rating in a report on Thursday, October 1st. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Royal Bank Of Canada raised their price target on shares of Danaher from $215.00 to $250.00 and gave the company an "outperform" rating in a report on Monday. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Barclays boosted their price objective on shares of Danaher from $230.00 to $255.00 and gave the stock an "overweight" rating in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and an average price target of $235.23.
Read Our Latest Stock Analysis on DHR
Danaher Stock Up 1.2%
DHR stock opened at $220.15 on Friday. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $154.76 billion, a P/E ratio of 39.10, a PEG ratio of 2.71 and a beta of 0.76. The firm has a 50 day simple moving average of $211.38 and a 200-day simple moving average of $194.62.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts' consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period last year, the firm earned $0.77 earnings per share. The company's revenue for the quarter was up 5.5% compared to the same quarter last year. On average, equities research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher's payout ratio is 28.42%.
Danaher Profile
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.
The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.
Featured Stories
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.